Shimada H, Kawagoe M, Kamenosono T, Kiyozumi M, Funakoshi T, Kojima S
Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
Toxicology. 1991;68(2):157-67. doi: 10.1016/0300-483x(91)90018-v.
Sodium N-benzyl-D-glucamine dithiocarbamate (BGD), sodium N-p-hydroxymethylbenzyl-D-glucamine dithiocarbamate (HBGD), sodium N-p-carboxybenzyl-D-glucamine dithiocarbamate (CBGD) and sodium N-p-methoxybenzyl-D-glucamine dithiocarbamate (MeOBGD) were evaluated for their efficacy in the distribution and excretion of cadmium in mice exposed to cadmium. Mice were injected i.p. with 109CdCl2 (1 mg Cd/kg and 74 kBq of 109Cd/animal) and 30 min or 24 h later, they were injected with chelating agents (400 mumol/kg). At 30 min after treatment with cadmium, these chelating agents all significantly enhanced the biliary excretion of cadmium, and HBGD and CBGD significantly increased the urinary excretion of the metal. At 24 h after cadmium injection, BGD, HBGD, and MeOBGD significantly increased the biliary excretion of cadmium and HBGD was the most effective on the biliary excretion of the metal. These chelating agents were effective in mobilizing cadmium from the liver at 30 min after cadmium treatment. At 24 h after cadmium treatment, HBGD and MeOBGD effectively depressed cadmium content in the liver and only HBGD among these chelating agents significantly reduced the cadmium content in the kidney. In another experiment, mice were injected i.p. with 109CdCl2 and three days later, they were injected with chelating agents every other day for 2 weeks. HBGD was the most effective on the fecal and urinary excretions of cadmium. The hepatic cadmium content was decreased after HBGD or MeOBGD injection. The injection of HBGD caused a much greater decrease in renal cadmium content than did BGD, CBGD, or MeOBGD. The results of this study indicated that the injection of HBGD to mice pretreated with cadmium can remove cadmium from the body, mainly through fecal excretion, without redistribution of cadmium to other tissues such as the brain, testes, and heart, more effectively than that of BGD, CBGD, or MeOBGD.
对 N-苄基-D-葡糖胺二硫代氨基甲酸钠(BGD)、N-对羟甲基苄基-D-葡糖胺二硫代氨基甲酸钠(HBGD)、N-对羧基苄基-D-葡糖胺二硫代氨基甲酸钠(CBGD)和 N-对甲氧基苄基-D-葡糖胺二硫代氨基甲酸钠(MeOBGD)在镉暴露小鼠体内镉的分布和排泄方面的功效进行了评估。给小鼠腹腔注射 109CdCl2(1 毫克镉/千克,每只动物 74 千贝克勒尔的 109Cd),30 分钟或 24 小时后,给它们注射螯合剂(400 微摩尔/千克)。在用镉处理 30 分钟后,这些螯合剂均显著增强了镉的胆汁排泄,且 HBGD 和 CBGD 显著增加了该金属的尿液排泄。在注射镉 24 小时后,BGD、HBGD 和 MeOBGD 显著增加了镉的胆汁排泄,且 HBGD 对该金属的胆汁排泄最为有效。这些螯合剂在镉处理 30 分钟后能有效地从肝脏中动员镉。在镉处理 24 小时后,HBGD 和 MeOBGD 有效地降低了肝脏中的镉含量,且在这些螯合剂中只有 HBGD 显著降低了肾脏中的镉含量。在另一项实验中,给小鼠腹腔注射 109CdCl2,三天后,每隔一天给它们注射螯合剂,持续 2 周。HBGD 对镉的粪便和尿液排泄最为有效。注射 HBGD 或 MeOBGD 后肝脏中的镉含量降低。与 BGD、CBGD 或 MeOBGD 相比,注射 HBGD 导致肾脏中镉含量的降低幅度更大。本研究结果表明,给预先用镉处理的小鼠注射 HBGD 可将镉从体内清除,主要通过粪便排泄,且不会使镉重新分布到其他组织如脑、睾丸和心脏,比 BGD、CBGD 或 MeOBGD 更有效。